EUVIMEDEUVIMED entdecken
Crossref

HeRO graft—The results of the cologne single center study

Vladimir Matoussevitch iD, Bernhard Dorweiler, Egan Kalmykov iD

Vascular · 2025

DOI: 10.1177/17085381241259645 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Vascular, 2025. Verfasst von Vladimir Matoussevitch und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Vascular and Endovascular Surgery, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany. Hauptthemen laut MEDLINE: Blood Vessel Prosthesis, Blood Vessel Prosthesis Implantation, Arteriovenous Shunt, Surgical, Renal Dialysis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The HeRO graft is a technique for vascular access in patients with limited treatment options; however, the published results with the HeRO graft are diverging. We therefore conducted a single-center study.

Methods

Patient records between July 2014 and February 2020 from Vascular Access Unit of the Department of Vascular and Endovascular Surgery of University Clinic of Cologne (Germany) were reviewed. Retrospective data was analysed from patients with a HeRo graft ( n = 18).

Results

Eighteen patients were enrolled in the study. The mean age of the patients was 62.8 ± 17.24 years. During the follow-up period, no patients died from complications related to the HeRO graft. Each patient had a mean of 1.94 concomitant diseases. The primary patency rates of the HeRO graft at 3, 6, 12, 18, and 24 months were 61.1%, 50%, 16.7%, 11.1%, and 5.6%, respectively. The secondary patency rates at the same time intervals were 77.8%, 72.8%, 55.6% 55.6%, and 55.6%, respectively. There were 44 re-operations per year, or 2.4 operations per patient. The main cause of acute complications was acute graft occlusions after HERO graft implantation. An infection after the graft implantation occurred in five (27.7%) patients, leading to graft explanation in 2 cases.

Conclusion

The use of the HERO graft is a valuable alternative method for providing a durable dialysis access in patients with limited access options. The secondary patency and survival are good with a low infection rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Blood Vessel ProsthesisBlood Vessel Prosthesis ImplantationArteriovenous Shunt, SurgicalRenal DialysisHumansRetrospective StudiesVascular PatencyMiddle AgedMaleFemaleTreatment OutcomeAgedTime FactorsGraft Occlusion, VascularRisk FactorsGermanyProsthesis DesignAdultProsthesis-Related InfectionsReoperation

Stichwörter der Autor:innen

HERO Graftdialysespatencyshuntsurvival

Autor:innen und Institutionen

  • Department of Vascular and Endovascular Surgery, University of Cologne, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
  • Brandenburg Medical School Theodor Fontane, Department of Vascular and Endovascular Surgery, Brandenburg University Clinic, Brandenburg, Germany.

ORCID-Profile: Vladimir Matoussevitch, Egan Kalmykov

Zitieren

APA

Matoussevitch, V., Dorweiler, B., & Kalmykov, E. (2025). HeRO graft—The results of the cologne single center study. Vascular. https://doi.org/10.1177/17085381241259645

Vancouver

Matoussevitch V, Dorweiler B, Kalmykov E. HeRO graft—The results of the cologne single center study. Vascular. 2025. doi:10.1177/17085381241259645

BibTeX
@article{Matoussevitch2025,
  author = {Matoussevitch, Vladimir and Dorweiler, Bernhard and Kalmykov, Egan},
  title = {HeRO graft—The results of the cologne single center study},
  journal = {Vascular},
  year = {2025},
  doi = {10.1177/17085381241259645}
}
Kostenlos starten →